Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics announced that its VP-001 drug development program has received Rare Pediatric Disease designation from the US FDA, specifically targeting PRPF31-associated vision loss. This designation is significant as it encourages the development of treatments for rare pediatric diseases, potentially enhancing PYC’s market position and providing new hope for patients with Retinitis Pigmentosa type 11.
More about PYC Therapeutics Limited
PYC Therapeutics is a clinical-stage biotechnology firm focused on developing RNA-based precision therapies for genetic diseases lacking treatment options. The company leverages a proprietary drug delivery platform to enhance the effectiveness of RNA therapies, targeting monogenic diseases with high clinical success rates.
YTD Price Performance: -12.12%
Average Trading Volume: 330,529
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$515.6M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.
